FDA approves groundbreaking new drug for pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, a novel pill designed to combat the most common form of pancreatic cancer. This approval offers American patients a significantly more effective treatment against one of the deadliest cancers.

The first-of-its-kind pill, branded as Rasonque by Revolution Medicines, targets a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases. This therapeutic approach has long eluded drugmakers.

In a study, patients taking daraxonrasib nearly doubled their survival time compared to those receiving standard chemotherapy. The drug also demonstrated fewer severe side effects. The company-funded study involved 500 patients with metastatic cancer that had become resistant to prior treatments. Those receiving the new treatment lived for a median of 13.2 months, a stark contrast to the 6.7 months seen in the chemotherapy group.

Pancreatic cancer remains one of the most lethal forms of the disease, largely due to difficulties in early detection. The American Cancer Society estimates approximately 67,000 new cases will be diagnosed in the U.S. this year, with over 52,000 deaths. The overall five-year survival rate is currently only 13%.

The drug had previously garnered public attention when former U.S. Senator Ben Sasse shared his experience with reduced pain while taking it. This surge in public interest prompted the FDA to allow "expanded access" before the drug's official approval for eligible patients. FDA regulators approved the drug more than six months ahead of their target date, emphasizing their commitment to delivering meaningful treatments to patients swiftly.

“

It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.